Antimicrobial Wound Gel for Surgical Site Complications
Trial Summary
What is the purpose of this trial?
This is a single-site, prospective, clinical study of subjects that are scheduled to undergo either total hip or total knee arthroplasties. It is anticipated that surgical wounds treated with SurgX will exhibit reduced surgical site complication rates and improved post-operative treatment outcomes by potentially decreasing site bioburden of both free-floating and biofilm-entrenched organisms.
Research Team
Giles Scuderi
Principal Investigator
Northwell Health
Eligibility Criteria
This trial is for adults over 18 who are scheduled for primary hip or knee replacement surgery and can consent to participate. They must be able to follow the study's procedures throughout its duration. People with allergies to any study products, mental impairments preventing proper consent, or those considered vulnerable under specific federal regulations cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive SurgX™ Antimicrobial Wound Gel applied over incision after closure and re-applied at first dressing change on day of discharge
Follow-up
Participants are monitored for surgical site complications and wound healing outcomes
Treatment Details
Interventions
- Standard of Care
- SurgX Antimicrobial Wound Gel
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwell Health
Lead Sponsor
Next Science
Collaborator
Next Science TM
Industry Sponsor